170 related articles for article (PubMed ID: 28828897)
1. Preoperative nutritional risk assessment in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis.
Banaste N; Rousset P; Mercier F; Rieussec C; Valette PJ; Glehen O; Passot G
Int J Hyperthermia; 2018 Aug; 34(5):589-594. PubMed ID: 28828897
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer.
van Vugt JL; Braam HJ; van Oudheusden TR; Vestering A; Bollen TL; Wiezer MJ; de Hingh IH; van Ramshorst B; Boerma D
Ann Surg Oncol; 2015 Oct; 22(11):3625-31. PubMed ID: 25672564
[TBL] [Abstract][Full Text] [Related]
3. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Chemama S; Bayar MA; Lanoy E; Ammari S; Stoclin A; Goéré D; Elias D; Raynard B; Antoun S
Ann Surg Oncol; 2016 Nov; 23(12):3891-3898. PubMed ID: 27352205
[TBL] [Abstract][Full Text] [Related]
5. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
6. The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.
Agalar C; Sokmen S; Arslan C; Altay C; Basara I; Canda AE; Obuz F
Tech Coloproctol; 2020 Apr; 24(4):301-308. PubMed ID: 32080800
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Nutrition Status and Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Reece L; Dragicevich H; Lewis C; Rothwell C; Fisher OM; Carey S; Alzahrani NA; Liauw W; Morris DL
Ann Surg Oncol; 2019 Aug; 26(8):2622-2630. PubMed ID: 31123932
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
9. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
10. Perioperative nutritional assessment and interventions in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): A systematic review.
Gearing PF; Hawke JA; Mohan H; Heriot AG; Khan A; Beaumont A; Laing E; Waters PS
Eur J Surg Oncol; 2023 May; 49(5):902-917. PubMed ID: 36872111
[TBL] [Abstract][Full Text] [Related]
11. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Computed Tomography Measurements of Sarcopenia on Postoperative and Oncologic Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Al Khaldi M; Fellouah M; Drolet P; Côté J; Trilling B; Brind'Amour A; Dugas A; Tremblay JF; Fortin S; De Guerké L; Auclair MH; Dubé P; Soucisse M; Sideris L
Curr Oncol; 2022 Nov; 29(12):9314-9324. PubMed ID: 36547144
[TBL] [Abstract][Full Text] [Related]
13. Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Devilee RA; Simkens GA; van Oudheusden TR; Rutten HJ; Creemers GJ; Ten Tije AJ; de Hingh IH
Ann Surg Oncol; 2016 Sep; 23(9):2841-8. PubMed ID: 27044447
[TBL] [Abstract][Full Text] [Related]
14. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
15. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
16. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
17. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients: Complete Cytoreduction Is Feasible and Crucial for Improved Survival Despite High Carcinomatosis Index.
Naffouje SA; Salti GI
Anticancer Res; 2018 Jan; 38(1):441-448. PubMed ID: 29277807
[TBL] [Abstract][Full Text] [Related]
19. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
20. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Bong TSH; Tan GHC; Chia C; Soo KC; Teo MCC
Int J Clin Oncol; 2017 Jun; 22(3):511-518. PubMed ID: 28138878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
